Previous 10 | Next 10 |
2024-02-11 01:45:00 ET In biotech, it's often difficult to tell whether bad news for one company will also be bad news for a competitor, or vice versa. Between using different approaches to therapy development, working with regulatory regimes in different countries, and targeting different ...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
2024-02-04 03:05:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Equity markets generat...
2024-01-31 15:01:32 ET More on Sarepta Therapeutics Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clin...
2024-01-30 12:25:46 ET More on PepGen PepGen: Long Road Ahead Seeking Alpha’s Quant Rating on PepGen Historical earnings data for PepGen Financial information for PepGen Read the full article on Seeking Alpha For further details see: ...
2024-01-29 07:53:11 ET More on Sarepta Therapeutics Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clin...
At target dose (~30 mg/kg), SRP-5051 dosed monthly resulted in mean dystrophin expression of 5.17% and mean exon skipping of 11.11% at 28 weeks (n=20) The data support a positive benefit-risk profile for SRP-5051 Sarepta will host a conference call at 8:30 a.m. Eastern tim...
2024-01-25 09:45:00 ET Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for rare diseases or, at least, for conditions with severe un...
2024-01-25 06:14:55 ET Summary Interim phase 1 data update using 4D-710 for the treatment of patients with Cystic Fibrosis expected in mid-2024. Program update on advancement of 4D-710 into pivotal study either alone or in combination with CFTR modular expected in Q1 of 2024. ...
2024-01-24 04:31:39 ET Summary Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapy and RNA-targeted treatments for rare diseases such as Duchenne muscular dystrophy and Limb-girdle muscular dystrophy. The company's FDA-approved products, includin...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...